Research programme: KCNQ potassium channel agonists - Icagen, Inc.
Alternative Names: ICA-27243; ICA-69673Latest Information Update: 04 Nov 2017
At a glance
- Originator Icagen
- Developer Icagen, Inc.
- Class Analgesics; Antiepileptic drugs; Benzamides; Small molecules
- Mechanism of Action KCNQ potassium channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Epilepsy; Neuropathic pain
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Epilepsy in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Neuropathic-pain in USA (PO)
- 12 Dec 2005 Data presented at the 35th Annual Meeting of the Society for Neuroscience (SfN-2005) have been added to the Epilepsy and seizure disorders, and Pain pharmacodynamics sections ,,